본문 바로가기

Real-world outcomes of ponatinib in heavily pretreated patients with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q2Scopus Q2
저널
ANNALS OF HEMATOLOGY105(7) · #315 · 2026
피인용
Web of Science 1Scopus 0
FWCI (Scopus)
0
JCR IF
JCR 2024 2.4
ISSN
0939-5555

저자

  1. Lee, Seok제1저자Ewha Womans Univ, Mokdong Hosp, Dept Hematol, Seoul, South Korea
  2. Kim, Hyeoung-JoonChonnam Natl Univ, Hematol Oncol, Hwasun Hosp, Hwasun, Jeonranam Do, South Korea
  3. Cheong, June-WonYonsei Univ, Gangnam Severance Hosp, Div Hematol, Coll Med, Seoul, South Korea
  4. 신호진Pusan Natl Univ Hosp, Dept Internal Med, Div Hematol Oncol, Pusan, South Korea
  5. Kong, Jee HyunWonju Severance Christian Hosp, Dept Internal Med, Div Oncol & Hematol, Wonju, South Korea
  6. Sohn, Sang KyunKyungpook Natl Univ Hosp, Dept Hematol Oncol, Daegu, South Korea
  7. Yoon, Sung-SooSeoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea
  8. Zang, Dae YoungHallym Univ, Sacred Heart Hosp, Dept Internal Med, Div Hematol Oncol, Anyang Si, South Korea
  9. Jung, Chul WonSungkyunkwan Univ, Samsung Med Ctr, Dept Med, Div Hematol Oncol,Sch Med, Seoul, South Korea
  10. Kim, Jeong-ACatholic Univ Korea, St Vincents Hosp, Coll Med, Dept Internal Med, Seoul, South Korea
  11. Lee, Sung-EunCatholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Hematol, Seoul, South Korea
  12. Lee, Won SikInje Univ, Dept Hematol & Oncol, Internal Med, Busan Paik Hosp,Coll Med, Busan, South Korea
  13. Choi, YunsukUniv Ulsan, Coll Med, Asan Med Ctr, Dept Hematol, Seoul, South Korea
  14. Kim, InhoSeoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea
  15. Han, Jae JoonKyung Hee Univ, Coll Med, Dept Hematol & Med Oncol, Seoul, South Korea
  16. Kim, Min KyoungYeungnam Univ, Coll Med, Dept Internal Med, Div Hematol Oncol, Daegu, South Korea
  17. Chong, So YoungCHA Univ, Sch Med, Dept Internal Med, CHA Bundang Med Ctr, Seongnam, South Korea
  18. Kim, Da JungKosin Univ, Gospel Hosp, Dept Internal Med, Div Hematol Oncol,Coll Med, Busan, South Korea
  19. Jo, Deog-YeonChungnam Natl Univ Hosp, Dept Internal Med, Div Hematol & Oncol, Daejeon, South Korea
  20. Kim, HawkGachon Univ, Gil Med Ctr, Coll Med, Div Hematol, Incheon, South Korea
  21. Kwak, Jae-YongJeonbuk Natl Univ, Med Sch, Dept Internal Med, Jeonju, South Korea
  22. Lee, Je-HwanUniv Ulsan, Coll Med, Asan Med Ctr, Dept Hematol, Seoul, South Korea
  23. Uhm, JieunHanyang Univ, Seoul Hosp, Coll Med, Div Hematol & Oncol,Dept Internal Med, Seoul, South Korea
  24. Lee, SewonEwha Womans Univ, Mokdong Hosp, Dept Hematol, Seoul, South Korea
  25. Lee, Min-YiKorea Otsuka Pharmaceut Co Ltd, Seoul, South Korea
  26. Kim, Dong-Wook교신저자Uijeongbu Eulji Med Ctr, Dept Hematol, Uijongbu, South Korea

초록

To evaluate the real-world efficacy and safety of ponatinib, we conducted a multicenter, prospective post-marketing surveillance study in patients with chronic phase (CP), accelerated phase (AP), or blast phase (BP) chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL), who were resistant or intolerant to prior tyrosine kinase inhibitors (TKIs) or harbored the T315I mutation. A total of 148 patients were enrolled across 24 sites: 115 with CML (92 CP-CML, 12 AP-CML, 11 BP-CML) and 33 with Ph + ALL. Ponatinib was administered as third-line therapy in 70 patients (47.3%), and 127 (85.8%) initiated treatment at 45 mg once daily. Sixty-three patients (42.6%) began ponatinib due to resistance or intolerance to prior TKIs. In CP-CML, the overall major molecular response (MMR) rate was 43.2% (35/81), with a cumulative MMR incidence of 23.9% at week 24 among patients without prior MMR. In Ph + ALL, the overall MMR and complete cytogenetic response (CCyR) rates were 82.4% (14/17) and 75.0% (3/4), respectively. CP-CML patients receiving ponatinib as earlier-line therapy achieved higher MR4.5 rates than those treated later (47.4% vs. 16.1%, p = 0.011). The most common adverse drug reactions were rash (21.6%, 32/148), hypertension (12.2%, 18/148), and pyrexia (10.1%, 15/148); two vascular occlusive events occurred. Ponatinib showed favorable real-world efficacy and manageable safety in Korean patients. Early, high-dose therapy suggests a trend toward deep molecular responses, supporting its clinical benefit in real-world practice. (ClinicalTrials.gov Identifier: NCT03709017; registered October 15, 2018)

키워드

PonatinibPost-marketing surveillanceChronic myeloid leukemiaAcute lymphoblastic leukemiaASIAN PATIENTS

식별자

Scopus EID
2-s2.0-105043758430
WoS UID
001810672700001